Vera Therapeutics Inc VERA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/18/21 EDT
14.09quote price arrow down-1.33 (-8.63%)
Volume
78,018
52 week range
11.30 - 26.97

...

Loading . . .
  • Open15.37
  • Day High15.70
  • Day Low14.06
  • Prev Close15.42
  • 52 Week High26.97
  • 52 Week High Date05/20/21
  • 52 Week Low11.30
  • 52 Week Low Date05/14/21

Key Stats

  • Market Cap297.72M
  • Shares Out21.13M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

KEY STATS

  • Open15.37
  • Day High15.70
  • Day Low14.06
  • Prev Close15.42
  • 52 Week High26.97
  • 52 Week High Date05/20/21
  • 52 Week Low11.30
  • 52 Week Low Date05/14/21
  • Market Cap297.72M
  • Shares Out21.13M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-2.61
  • P/E (TTM)-5.40
  • Fwd P/E (NTM)-2.39
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vera Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Vera Therapeutics, Inc. is a clinical stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells...
Marshall Fordyce M.D.
Chief Executive Officer
Jonathan Wolter
Chief Financial Officer
Address
170 Harbor Way, 3rd Floor
South San Francisco, CA
94080
United States